Conditions: Cerebral Infarction
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 2800
Healthy volunteers: no

Brief summary:
The purpose of this study is to investigate the efficacy of cilostazol in preventing recurrence of cerebral infarction and the safety of long-term administration of the drug (100 mg, twice daily) in patients with cerebral infarction (excluding cardiogenic cerebral embolism) in a multi-center, double-blind, parallel-group comparison with aspirin (81 mg, once daily).

Detailed description:

Arms:
arm 1: cilostazol arm 2: Aspirin

Interventions: intervention 1: Cilostazol intervention 2: Aspirin
Intervention descriptions: intervention 1: oral tablet, 100 mg twice a day and placebo of aspirin once a day, 1 to 5years intervention 2: oral tablet, placebo of cilostazol twice a day and 81 mg once a day, 1 to 5 years

Protocol document: